On December 1, 2025, Tecan Group acquired the assets of Wako Automation, including the Director™ scheduling software, to enhance its laboratory automation capabilities and expand its product portfolio in response to growing demand for integrated automation solutions in the biopharma sector.

Information on the target

The Tecan Group, a prominent player in laboratory automation, has successfully acquired the assets of Wako Automation, which includes the highly regarded Director™ scheduling software and select hardware modules. This strategic acquisition was finalized on December 1, 2025, and is poised to enhance Tecan's offerings in the automation sector significantly.

By integrating Wako Automation's advanced scheduling capabilities, Tecan aims to provide its customers with enhanced flexibility and efficiency in managing complex workflows. The acquisition aligns with Tecan's vision to expand its market presence beyond traditional liquid-handling solutions, reinforcing its leadership in the laboratory automation industry.

Industry overview in the target’s specific country

Switzerland is recognized as a global hub for life sciences and biotechnology, with a robust infrastructure supporting research and development. The laboratory automation sector in Switzerland is experiencing sig

View Source

Similar Deals

Galenica Labor Team Group

2025

Other Pharmaceuticals (NEC) Switzerland
Galderma Galderma shares

2025

Other Pharmaceuticals (NEC) Switzerland
Galenica Labor Team Gruppe

2025

Other Pharmaceuticals (NEC) Switzerland
Addex Therapeutics Stalicla

2025

Other Proprietary & Advanced Pharmaceuticals Switzerland
Tecan Group Wako Automation

2025

Other Biotechnology & Medical Research (NEC) Switzerland
Sonova SilentCloud™

2025

Other Healthcare Facilities & Services (NEC) Switzerland

Tecan Group

invested in

Wako Automation assets

in 2025

in a Other deal

Disclosed details

Revenue: $1,062M

Deal Parameters
Industry
Country
Seller type

Sign Up to Dealert